Global X Genomics & Biotechnology ETF (GNOM)

The science of reading and editing human DNA has moved from the laboratory into clinical use, and the list of companies competing to shape that shift spans sequencing machines, genetic therapies, personalized diagnostics, and the software that makes sense of genetic data.

Genomics is not a niche. It is the future of how medicine is practiced.

The Global X Genomics & Biotechnology ETF (ticker GNOM) is built around that conviction. It tracks a portfolio of companies for whom genomic innovation is not a side project but a central driver of revenue and competitive position.

The sector: genomics as an industry tier

Genomics is not a single company; it is a tier of businesses built around understanding, sequencing, and editing the human genome. The industry includes sequencing-equipment makers (the machines and reagents that read DNA), gene-therapy firms (companies working to fix genetic disease at the source), diagnostic businesses (tests for genetic risk or disease), bioinformatics platforms (software that processes genetic data), and broader biotech firms that apply genomic tools to drug discovery.

GNOM’s mandate is to hold a diversified basket of these companies — not a pure play on one segment, but a concentration of firms for which genomics or genetic science is a primary business driver. The logic is straightforward: as genomics moves from research curiosity into routine medical practice, the companies enabling that shift will grow. A thematic ETF bets that the industry will expand faster than the broader stock market, and faster than traditional sector-focused alternatives would capture.

The fund’s construction and holdings

GNOM tracks a custom index of genomics and biotechnology companies. The index is not a broad-market proxy; it is purpose-built to isolate firms with material exposure to genomic innovation. That means the fund holds a smaller, more concentrated list than a traditional biotech ETF. The emphasis is on purity: companies whose revenues or competitive positioning depend substantially on genomic tools or insights.

The index is reviewed and rebalanced periodically. New companies enter the genomics space; others shift their business emphasis. Like most thematic ETFs, GNOM does not track a government standard index. Global X designs the index to fit the theme, which gives it flexibility but also means the composition is proprietary and subject to the fund sponsor’s interpretation of what counts as a genomics play.

This concentration is the fund’s defining characteristic. GNOM will not perfectly track the broad biotech sector or healthcare in general. In quarters when pure genomics businesses outperform, GNOM may beat a traditional healthcare ETF; in quarters when legacy pharma or medical-device firms surge, GNOM may lag. That tracking error is deliberate. You are betting on genomics specifically, not healthcare broadly.

Costs and trading mechanics

GNOM trades on the NASDAQ like any stock. You buy and sell shares at market prices during market hours. The bid-ask spread is typically tight for a thematic ETF, though it can widen in volatile markets.

The fund charges an expense ratio to cover management and trading costs. For a thematic, actively-managed ETF, the ratio is modest — lower than an actively-managed mutual fund with a dedicated research team, but higher than a simple index tracker holding hundreds of stocks with minimal turnover. You pay for the conviction that genomics deserves its own dedicated fund.

The trade-off is critical: lower costs favour the patient investor holding for years. Higher costs weigh on returns if the fund simply tracks the broader biotech market. The case for GNOM rests on whether genomic companies will outpace healthcare in general; if that fails, the extra costs will drag down your returns.

Concentration and sector risks

A thematic ETF concentrates its bet, which means both upside and downside are amplified. When genomic science is in favour — regulatory approvals for new therapies, breakthrough sequencing results, venture funding flowing freely — GNOM can outperform. When the sector stumbles — a major clinical trial failure, slowing venture investment, regulatory setbacks — GNOM falls harder than the broader market.

The fund is also exposed to the intrinsic risks of the biotechnology industry. Drug development is slow and expensive; many promising therapies fail late in development. Gene therapy is newer than traditional small-molecule drugs, so the regulatory path is still evolving. Reimbursement — the willingness of health systems and insurance companies to pay for genomic tests and therapies — is not guaranteed and changes with policy.

Concentration risk is material. A large holding entering trouble can move GNOM’s price meaningfully because the portfolio is smaller and more focused than a broad-market fund. In extreme cases, a bankruptcy or clinical failure can be deeply painful for investors holding the fund.

Finally, liquidity in the underlying stocks matters. GNOM itself is liquid to trade, but if a significant number of the companies it holds are small or thinly traded, that increases friction in the fund’s ability to rebalance without moving prices.

How to research this fund

Read the fund’s prospectus and fact sheet (available from Global X and the fund’s website), which list the current holdings and the methodology for selecting them. Track the fund’s one-year, three-year, and five-year returns relative to the broader NASDAQ biotech index to see whether the thematic focus has paid off or disappointed.

Watch for major holdings that stumble. A single company trouble can materially affect a concentrated fund in ways a broad fund would absorb. Understand what triggered your interest: a single promising news story is not a sufficient foundation. If you own GNOM because you believe the shift to genetic medicine is one of the defining economic stories of your investing life, and you are comfortable holding through multi-year cycles of enthusiasm and disappointment, it is a coherent choice.